High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases

Amy E. Dezern, Michelle Petri, Daniel B. Drachman, Doug Kerr, Edward R. Hammond, Jeanne Kowalski, Hua Ling Tsai, David M. Loeb, Grant Anhalt, Fredrick Wigley, Richard J. Jones, Robert A. Brodsky

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

High-dose cyclophosphamide has long been used as an anticancer agent, a conditioning regimen for hematopoietic stem cell transplantation, and a potent immunosuppressive agent in autoimmune diseases including aplastic anemia. High-dose cyclophosphamide is highly toxic to lymphocytes but spares hematopoietic stem cells because of their abundant levels of aldehyde dehydrogenase, the major mechanism of cyclophosphamide inactivation. High-dose cyclophosphamide therapy induces durable remissions in most patients with acquired aplastic anemia. Moreover, high-dose cyclophosphamide without hematopoietic stem cell rescue has shown activity in a variety of other severe autoimmune diseases.Here we review the history of cyclophosphamide as it applies to aplastic anemia and other autoimmune diseases. We include historical data from early patients treated for aplastic anemia as well as data from 140 patients from an observational retrospective study in a single tertiary care hospital. This latter component was designed to assess the safety and efficacy of high-dose cyclophosphamide therapy without stem cell rescue in patients with refractory autoimmune diseases. We analyzed the 140 patients with severe, progressive autoimmune diseases treated. All patients discussed here received cyclophosphamide, 50 mg/kg per day for 4 consecutive days. Response, relapse, and overall survival were measured. Response was defined as a decrease in disease activity in conjunction with a decrease or elimination of immune-modulating drugs. Relapse was defined as worsening disease activity and/or a requirement for an increase in dose of, or administration of new, immunosuppressive medications.Hematologic recovery occurred in all patients. The overall response rate was 94%, and 44% of those patients remained progression free with a median follow-up of 36 months (range, 1-120 mo) for the 140 patients analyzed together. The overall actuarial and event-free survival across all diseases at 60 months was 90.7% and 20.6%, respectively. High-dose cyclophosphamide without stem cell rescue is well tolerated and induces a high rate of remission in severe autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalMedicine
Volume90
Issue number2
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Aplastic Anemia
Cyclophosphamide
Autoimmune Diseases
Stem Cells
Immunosuppressive Agents
Hematopoietic Stem Cells
Recurrence
Aldehyde Dehydrogenase
Poisons
Hematopoietic Stem Cell Transplantation
Tertiary Healthcare
Tertiary Care Centers
Antineoplastic Agents
Disease-Free Survival
Observational Studies
Retrospective Studies
History
Lymphocytes
Safety
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dezern, A. E., Petri, M., Drachman, D. B., Kerr, D., Hammond, E. R., Kowalski, J., ... Brodsky, R. A. (2011). High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine, 90(2), 89-98. https://doi.org/10.1097/MD.0b013e318210e685

High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. / Dezern, Amy E.; Petri, Michelle; Drachman, Daniel B.; Kerr, Doug; Hammond, Edward R.; Kowalski, Jeanne; Tsai, Hua Ling; Loeb, David M.; Anhalt, Grant; Wigley, Fredrick; Jones, Richard J.; Brodsky, Robert A.

In: Medicine, Vol. 90, No. 2, 01.03.2011, p. 89-98.

Research output: Contribution to journalArticle

Dezern, AE, Petri, M, Drachman, DB, Kerr, D, Hammond, ER, Kowalski, J, Tsai, HL, Loeb, DM, Anhalt, G, Wigley, F, Jones, RJ & Brodsky, RA 2011, 'High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases', Medicine, vol. 90, no. 2, pp. 89-98. https://doi.org/10.1097/MD.0b013e318210e685
Dezern, Amy E. ; Petri, Michelle ; Drachman, Daniel B. ; Kerr, Doug ; Hammond, Edward R. ; Kowalski, Jeanne ; Tsai, Hua Ling ; Loeb, David M. ; Anhalt, Grant ; Wigley, Fredrick ; Jones, Richard J. ; Brodsky, Robert A. / High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. In: Medicine. 2011 ; Vol. 90, No. 2. pp. 89-98.
@article{5051bd9a97b84bad9b360482ac997772,
title = "High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases",
abstract = "High-dose cyclophosphamide has long been used as an anticancer agent, a conditioning regimen for hematopoietic stem cell transplantation, and a potent immunosuppressive agent in autoimmune diseases including aplastic anemia. High-dose cyclophosphamide is highly toxic to lymphocytes but spares hematopoietic stem cells because of their abundant levels of aldehyde dehydrogenase, the major mechanism of cyclophosphamide inactivation. High-dose cyclophosphamide therapy induces durable remissions in most patients with acquired aplastic anemia. Moreover, high-dose cyclophosphamide without hematopoietic stem cell rescue has shown activity in a variety of other severe autoimmune diseases.Here we review the history of cyclophosphamide as it applies to aplastic anemia and other autoimmune diseases. We include historical data from early patients treated for aplastic anemia as well as data from 140 patients from an observational retrospective study in a single tertiary care hospital. This latter component was designed to assess the safety and efficacy of high-dose cyclophosphamide therapy without stem cell rescue in patients with refractory autoimmune diseases. We analyzed the 140 patients with severe, progressive autoimmune diseases treated. All patients discussed here received cyclophosphamide, 50 mg/kg per day for 4 consecutive days. Response, relapse, and overall survival were measured. Response was defined as a decrease in disease activity in conjunction with a decrease or elimination of immune-modulating drugs. Relapse was defined as worsening disease activity and/or a requirement for an increase in dose of, or administration of new, immunosuppressive medications.Hematologic recovery occurred in all patients. The overall response rate was 94{\%}, and 44{\%} of those patients remained progression free with a median follow-up of 36 months (range, 1-120 mo) for the 140 patients analyzed together. The overall actuarial and event-free survival across all diseases at 60 months was 90.7{\%} and 20.6{\%}, respectively. High-dose cyclophosphamide without stem cell rescue is well tolerated and induces a high rate of remission in severe autoimmune diseases.",
author = "Dezern, {Amy E.} and Michelle Petri and Drachman, {Daniel B.} and Doug Kerr and Hammond, {Edward R.} and Jeanne Kowalski and Tsai, {Hua Ling} and Loeb, {David M.} and Grant Anhalt and Fredrick Wigley and Jones, {Richard J.} and Brodsky, {Robert A.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1097/MD.0b013e318210e685",
language = "English (US)",
volume = "90",
pages = "89--98",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases

AU - Dezern, Amy E.

AU - Petri, Michelle

AU - Drachman, Daniel B.

AU - Kerr, Doug

AU - Hammond, Edward R.

AU - Kowalski, Jeanne

AU - Tsai, Hua Ling

AU - Loeb, David M.

AU - Anhalt, Grant

AU - Wigley, Fredrick

AU - Jones, Richard J.

AU - Brodsky, Robert A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - High-dose cyclophosphamide has long been used as an anticancer agent, a conditioning regimen for hematopoietic stem cell transplantation, and a potent immunosuppressive agent in autoimmune diseases including aplastic anemia. High-dose cyclophosphamide is highly toxic to lymphocytes but spares hematopoietic stem cells because of their abundant levels of aldehyde dehydrogenase, the major mechanism of cyclophosphamide inactivation. High-dose cyclophosphamide therapy induces durable remissions in most patients with acquired aplastic anemia. Moreover, high-dose cyclophosphamide without hematopoietic stem cell rescue has shown activity in a variety of other severe autoimmune diseases.Here we review the history of cyclophosphamide as it applies to aplastic anemia and other autoimmune diseases. We include historical data from early patients treated for aplastic anemia as well as data from 140 patients from an observational retrospective study in a single tertiary care hospital. This latter component was designed to assess the safety and efficacy of high-dose cyclophosphamide therapy without stem cell rescue in patients with refractory autoimmune diseases. We analyzed the 140 patients with severe, progressive autoimmune diseases treated. All patients discussed here received cyclophosphamide, 50 mg/kg per day for 4 consecutive days. Response, relapse, and overall survival were measured. Response was defined as a decrease in disease activity in conjunction with a decrease or elimination of immune-modulating drugs. Relapse was defined as worsening disease activity and/or a requirement for an increase in dose of, or administration of new, immunosuppressive medications.Hematologic recovery occurred in all patients. The overall response rate was 94%, and 44% of those patients remained progression free with a median follow-up of 36 months (range, 1-120 mo) for the 140 patients analyzed together. The overall actuarial and event-free survival across all diseases at 60 months was 90.7% and 20.6%, respectively. High-dose cyclophosphamide without stem cell rescue is well tolerated and induces a high rate of remission in severe autoimmune diseases.

AB - High-dose cyclophosphamide has long been used as an anticancer agent, a conditioning regimen for hematopoietic stem cell transplantation, and a potent immunosuppressive agent in autoimmune diseases including aplastic anemia. High-dose cyclophosphamide is highly toxic to lymphocytes but spares hematopoietic stem cells because of their abundant levels of aldehyde dehydrogenase, the major mechanism of cyclophosphamide inactivation. High-dose cyclophosphamide therapy induces durable remissions in most patients with acquired aplastic anemia. Moreover, high-dose cyclophosphamide without hematopoietic stem cell rescue has shown activity in a variety of other severe autoimmune diseases.Here we review the history of cyclophosphamide as it applies to aplastic anemia and other autoimmune diseases. We include historical data from early patients treated for aplastic anemia as well as data from 140 patients from an observational retrospective study in a single tertiary care hospital. This latter component was designed to assess the safety and efficacy of high-dose cyclophosphamide therapy without stem cell rescue in patients with refractory autoimmune diseases. We analyzed the 140 patients with severe, progressive autoimmune diseases treated. All patients discussed here received cyclophosphamide, 50 mg/kg per day for 4 consecutive days. Response, relapse, and overall survival were measured. Response was defined as a decrease in disease activity in conjunction with a decrease or elimination of immune-modulating drugs. Relapse was defined as worsening disease activity and/or a requirement for an increase in dose of, or administration of new, immunosuppressive medications.Hematologic recovery occurred in all patients. The overall response rate was 94%, and 44% of those patients remained progression free with a median follow-up of 36 months (range, 1-120 mo) for the 140 patients analyzed together. The overall actuarial and event-free survival across all diseases at 60 months was 90.7% and 20.6%, respectively. High-dose cyclophosphamide without stem cell rescue is well tolerated and induces a high rate of remission in severe autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=79952438500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952438500&partnerID=8YFLogxK

U2 - 10.1097/MD.0b013e318210e685

DO - 10.1097/MD.0b013e318210e685

M3 - Article

VL - 90

SP - 89

EP - 98

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 2

ER -